1246-C SAFETY AND EFFICACY OF REP 2139-MG-BASED THERAPY IN FRENCH PATIENTS WITH PRIOR FAILURE TO PEGIFN AND OR BULEVIRTIDE Marc Bourliere 1 , Veronique Loustaud-Ratti 2 , Christiane Stern 3 , Souad Benali 4 , Edouard Bardou-Jacquet 5 , Laurent Alric 6 , Lea Colombain 7 , Magdalena Meszaros 8 , Sophie Mtivier 9 , Michel Bazinet 10 , Laurence Lecomte 1 , Sandrine Francois 2 , Cecilia De Freitas 3 , Segolene Brichler 11 , Athenas Gerber 11 , Emmanuel Gordien 11 , Stephane Chevaliez 12 and Andrew Vaillant 10 , (1)Service Hpato-Gastro-Entrologie, Hpital Saint-Joseph, (2)Service dHpato-Gastroentrologie, CHU De Limoges, (3)Service dHpatologie, Hpital Beaujon, (4)Service Hpato-Gastroentrologie, Hpital Saint-Joseph, (5)Service Des Maladie Du Foie, CHU De Rennes, (6)Service De Mdecine Interne-Maladies Digestives, CHU Rangueil, Universit Toulouse 3, (7)Centre Hospitalier De Perpignan, (8)CHU Montpellier, Montpellier, France, (9)Service dHepatologie, CHU Rangueil, Universit Toulouse 3, (10)Replicor Inc., (11)CHU Avicenne, (12)Service De Virologie, Hpital Henri Mondor Background: REP 2139 blocks HBV subviral particle assembly and hepatitis delta antigen function, driving HBsAg loss in HBV infection and HBsAg / HDV RNA loss in HBV / HDV co-infection
ForteBio, a Pall business unit, has incorporated MAB230P into its second-generation Dip and Read Anti-HIS fiber optic biosensor
A substantial proportion of users reported prolonged exposure to testosterone or other anabolicandrogenic substances, further emphasizing the potential risk of long-term adverse health consequences
Bujanda 2006)
